

# Respiratory Vaccines Update

## Webinar 1

October 1<sup>st</sup>, 2024

Allie Staton, PharmD

Vaccine Confidence Strategist

Immunize Arkansas

Email: [allie@immunizear.org](mailto:allie@immunizear.org)



# UAMS Disclosure Policy

It is the policy of the University of Arkansas for Medical Sciences (UAMS) to ensure balance, independence, objectivity, and scientific rigor in all directly or jointly provided educational activities.

All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. The ACCME and ACPE describe relevant financial relationships as those in any amount occurring within the past 24 months that create a conflict of interest. *Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CE activity.*

# Disclosures

The following planners and speakers of this CE activity have no relevant financial relationships with ineligible companies to disclose:

Allie Staton, PharmD

The accreditation compliance reviewer has no relevant financial relationships with ineligible companies to disclose.

# Joint Accreditation Statement

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



# **Thank You to Our Supporters**

Thank you to Pfizer for the support of this webinar series.

# Credit Designation Statements

## **AMA Credit Designation Statement**

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **ACPE Credit Designation Statement**

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

## **ANCC Credit Designation Statement**

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

## **AAPA Credit Designation Statement**

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

# Continuing Education

## To receive Continuing Education:

- **You must attend this webinar as it is being presented.**
  - Attendance will be recorded via Zoom to determine if you were present.
  - If you are watching this as a recording, you will not be eligible to receive CE.
- **You must complete the Evaluation Survey following this webinar.**
  - A link to the Evaluation Survey will be posted in the chat at the end of the presentation.
  - **DEADLINE: Midnight on Wednesday, October 2<sup>nd</sup>.**
    - **No late evaluations will be accepted.** Please complete the survey ASAP.
  - The survey link will also be sent out tomorrow afternoon in a follow-up email.
- **Certificates of Completion for attending this course will be available after you complete the Evaluation Survey.**
  - After you complete the survey, you will be directed to Certificates of Completion website.
  - You will have to write your name on the Certificate.
  - A link to the Certificates of Completion will also be sent out tomorrow afternoon in a follow-up email.

# Webinar

- If you have a question during or after the webinar, please ask your question in the chat.
  - I will do my best to answer all questions before the end of the webinar.
- If you have a question after the webinar, please email Allie Staton.
  - Email: [allie@immunizear.org](mailto:allie@immunizear.org)



# Objectives

- Interpret current guidelines for respiratory vaccines.
- Recommend appropriate respiratory vaccines to patients and community members.
- Discuss current respiratory vaccine guidelines and recommendations.

# Topics

- Review current guidance for COVID-19 vaccines
- Discuss current RSV vaccine recommendations for patients ages 60 years and older
- Review RSV vaccine recommendations for pregnant patients

# IMPORTANT NOTE...

Insurance plans are **not required** to pay for vaccines if they are administered outside of the ACIP/CDC guidelines.

**NOTE: FDA approval and package inserts may not be the same as ACIP/CDC guidelines.**

If you prescribe and/or administer an immunization outside of ACIP/CDC guidelines...

- Please document the clinical reason for prescribing outside of guidelines
- Counsel the patient on why you recommend it
- Counsel the patient that they may have to pay out of pocket

# DON'T FORGET!

**A strong recommendation from a healthcare provider is important!**

Patients are more likely to choose to vaccinate if their healthcare providers make a **strong** recommendation for vaccination.

COVID-19

Immunizations

2024 - 2025

# COVID-19

Immunization Products

# COVID-19 Vaccine Products

Pfizer	Moderna	Novavax
mRNA	mRNA	Protein Subunit
6 months and older	6 months and older	12 years and older
<p><b><u>Products</u></b></p> <p><b>2024 – 2025 season</b></p> <ul style="list-style-type: none"> <li>• 6 months thru 4 years (vial)</li> <li>• 5 years thru 11 years (vial)</li> <li>• 12 years and older (PFS)</li> </ul>	<p><b><u>Products</u></b></p> <p><b>2024 – 2025 season</b></p> <ul style="list-style-type: none"> <li>• 6 months thru 11 years (PFS)</li> <li>• 12 years and older (PFS)</li> </ul>	<p><b><u>Products</u></b></p> <p><b>2024 – 2025 season</b></p> <ul style="list-style-type: none"> <li>• 12 years and older (PFS)</li> </ul>

# COVID-19

## Vaccine Recommendations



# COVID-19 Vaccines, 2024 - 2025

- **FDA: Monovalent JN.1 or KP.2 (strain of JN.1 lineage), if feasible**
- Children 6 months-4 years who are not previously vaccinated should get 3 doses of updated Pfizer or 2 doses of updated Moderna vaccine
  - Children 6 months-4 years who got a previous dose of vaccine should complete the series with the same vaccine
- All children aged 5-11 years should get 1 dose of updated Pfizer or Moderna vaccine
- People 12 years and older who are not previously vaccinated should get 1 dose of updated Pfizer or Moderna or 2 doses of updated Novavax vaccine
- People 12 years and older who are previously vaccinated should get 1 dose of updated Pfizer or Moderna or Novavax vaccine

RSV

Immunizations

2024 - 2025

# RSV

## Immunization Products

	<b>Abrysvo</b> <i>Pfizer</i>	<b>Arexvy</b> <i>GSK</i>	<b>mRESVIA</b> <i>Moderna</i>	<b>Beyfortus</b> (nirsevimab) <i>Sanofi and AstraZeneca</i>
<b>FDA approved for:</b> • Ages 60 and older	✓	✓	✓	✗
<b>ACIP/CDC recommended for:</b> • Ages 60-74 with risk factors • Everyone ages 75 and older	✓	✓	✓	✗
<b>FDA approved for:</b> • Ages 50-59 with increased risk of severe RSV	✗	✓	✗	✗
<b>ACIP/CDC recommended for:</b> • Ages 50-59 with increased risk of severe RSV	✗	✗	✗	✗
<b>FDA approved for:</b> • Use in pregnancy	✓	✗	✗	✗
<b>ACIP/CDC recommended for:</b> • Use in pregnancy	✓	✗	✗	✗
<b>FDA approved for:</b> • Use in infants	✗	✗	✗	✓
<b>ACIP/CDC recommended for:</b> • Use in infants	✗	✗	✗	✓

# RSV

## Immunizations for Older Adults

# RSV (adults)

Three RSV vaccines approved and recommended for adults ages 60 years and older.

	<b>Abrysvo</b> <i>Pfizer</i>	<b>Arexvy</b> <i>GSK</i>	<b>mRESVIA</b> <i>Moderna</i>
<b>FDA-approved use (for older adults)</b>	<ul style="list-style-type: none"> <li>Ages 60 years and older</li> </ul>	<ul style="list-style-type: none"> <li>Ages 60 years and older</li> <li>Ages 50-59 years who are at increased risk of LRTD caused by RSV</li> </ul>	<ul style="list-style-type: none"> <li>Ages 60 years and older</li> </ul>
<b>ACIP/CDC Recommendations (for older adults)</b>	<ul style="list-style-type: none"> <li>One single dose for:               <ul style="list-style-type: none"> <li>Adults ages 75 years and older</li> <li>Adults ages 60-74 years who are at increased risk for severe RSV disease</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>One single dose for:               <ul style="list-style-type: none"> <li>Adults ages 75 years and older</li> <li>Adults ages 60-74 years who are at increased risk for severe RSV disease</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>One single dose for:               <ul style="list-style-type: none"> <li>Adults ages 75 years and older</li> <li>Adults ages 60-74 years who are at increased risk for severe RSV disease</li> </ul> </li> </ul>

**NOTE: These vaccines are NOT recommended by ACIP/CDC for use in older adults under the age of 60 years.**

# Risk factors for severe RSV disease

- Cardiovascular diseases
  - Heart failure, CAD, congenital heart disease (excluding isolated hypertension)
- Lung disease
  - COPD, emphysema, asthma, interstitial lung disease, cystic fibrosis
- Advanced chronic kidney disease
  - Stages 4-5, dependence on hemodialysis or other renal replacement therapy
- Diabetes mellitus with end-organ damage
  - Diabetic nephropathy, neuropathy, retinopathy, or cardiovascular disease
- Severe obesity (BMI  $\geq 40$  kg/m<sup>2</sup>)
- Liver disorders
  - Cirrhosis
- Neurologic or neuromuscular conditions
  - Neuromuscular conditions causing impaired airway clearance or respiratory muscle weakness, excluding history of stroke without impaired airway clearance
- Hematologic disorders
  - Sickle cell disease, thalassemia
- Moderate or severe immunocompromise
  - Either due to medical condition or receipt of immunosuppressive medications or treatment

# Risk factors for severe RSV disease, continued.

- People who are frail\*
- People who reside in nursing homes or other long-term care facilities providing assistance with activities of daily living\*\*
- People with other chronic medical conditions or risk factors that a healthcare provider determines might increase the risk of severe disease due to a respiratory infection

\*Frailty is multidimensional geriatric syndrome and reflects a state of increased vulnerability to adverse health outcomes. Although there is no consensus definition, one frequently used tool is the Fried frailty phenotype in which frailty is defined as a clinical syndrome with three or more of the following symptoms present: unintentional weight loss (10lbs in the past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity.

\*\* Retirement communities and independent living communities for seniors are not considered long-term care facilities. Adults ages 60-74 living in these facilities may still be recommended to receive RSV vaccination if they have certain medical conditions (listed above and on previous slide.)



# RSV Vaccines (*adults ages 60 years and older*)

- **Abrysvo, Arexvy, and mRESVIA approved for:**
  - All adults ages 75 years and older
  - Adults ages 60 - 74 years who are at increased risk of severe RSV disease
- **Currently, only one dose is recommended.**
  - Administer prior to RSV season, if possible.
  - RSV season is typically October thru March.
  - **This is NOT a yearly recommendation. It is currently a "one and done" recommendation.**
- **Coadministration with other vaccines is acceptable.**
  - Efficacy of coadministration is not expected to be an issue.
    - Studies are ongoing.
  - Patients *may* experience more side effects when Abrysvo, Arexvy, or mRESVIA are administered with other vaccines.
    - Counsel appropriately.
  - Use your clinical judgment when deciding to coadminister.
    - Will the patient return for other vaccines?

# RSV

Immunizations to Protect Infants

# RSV Immunizations (*to protect infants*)

There are two immunizations recommended to prevent RSV lower respiratory tract infection in infants.

## 1. **Abrysvo (RSVpreF): *maternal vaccination***

- Administered to pregnant patient during 32 – 36 weeks gestation (during the months of September through January)
- **It is NOT currently recommended to administer a dose for each pregnancy**

## 2. **Beyfortus (nirsevimab): *long-lasting monoclonal antibody***

- Administered to infant after birth

Either maternal vaccination *or* monoclonal antibody is recommended, in most situations for newborns.

Administration of both is not needed for most infants.

# RSV

Immunizations for Pregnant Patients

# RSV (pregnancy)

One RSV vaccine approved for pregnant patients.

	<b>Abrysvo (RSVpreF) <i>Pfizer</i></b>
<b>FDA-approved use</b>	<ul style="list-style-type: none"><li>• Pregnant patients 32 – 36 weeks gestational age</li></ul>
<b>ACIP/CDC Recommendations</b>	<ul style="list-style-type: none"><li>• Administer one dose to pregnant patients during weeks 32 – 36 weeks of pregnancy during <b><i>September through January</i></b><ul style="list-style-type: none"><li>• <b>It is not currently recommended to administer a dose during each pregnancy.</b></li><li>• Only one dose is currently recommended.</li></ul></li></ul>

# Thank you!

Questions?

# References: COVID-19 Vaccines

## COVID-19 Vaccines, 2024-2025

- Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- FDA: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2024-2025>

## Pfizer (6 months – 11 years)

- <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine>
- Fact Sheet for HCPs: <https://www.fda.gov/media/167211/download?attachment>

## Comirnaty (12 years and older)

- <https://www.fda.gov/vaccines-blood-biologics/comirnaty>
- Package Insert: <https://www.fda.gov/media/151707/download?attachment>

## Moderna (6 months – 11 years)

- <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/moderna-covid-19-vaccine>
- Fact Sheet for HCPs: <https://www.fda.gov/media/167208/download?attachment>

## Spikevax (12 years and older)

- <https://www.fda.gov/vaccines-blood-biologics/spikevax>
- Package Insert: <https://www.fda.gov/media/155675/download?attachment>

## Novavax (12 years and older)

- <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted>
- Fact Sheet for HCPs: <https://www.fda.gov/media/159897/download?attachment>

# References: RSV Vaccines

- RSV Vaccines in Older Adults – MMWR
  - <https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm>
- Use of Pfizer RSV vaccine during pregnancy – MMWR
  - <https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm>
- Use of nirsevimab for prevention of RSV in infants and young children – MMWR
  - <https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm>
- Abrysvo Package Insert
  - <https://www.fda.gov/media/168889/download>
- Arexvy Package Insert
  - <https://www.fda.gov/media/167805/download>